References:
[1] LV Kalia, AE Lang, Parkinson’s disease, Lancet. 386 (2015) 896–912.
[2] N Zhao, Y Yang, L Zhang, et al, Quality of life in Parkinson’s disease: A systematic review and meta-analysis of comparative studies. CNS. Neurosci. Ther. 27 (2021) 270–279.
[3] V Bellou, L Belbasis, I Tzoulaki, et al, Environmental risk factors and Parkinson’s disease: An umbrella review of meta-analyses, Parkinsonism Relat. Disord. 23 (2016) 1–9.
[4] DA Butterfield, E Barone, C Mancuso, Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders, Pharmacol. Res. 64 (2011)180–186.
[5] J Yan, L Qiao, J Tian, et al, Effect of statins on Parkinson’s disease: A systematic review and meta-analysis, Medicine. 98 (2019) e14852.
[6] TN Poly, MM Islam, BA Walther, et al, Exploring the Association between Statin Use and the Risk of Parkinson’s Disease: A Meta-Analysis of Observational Studies, Neuroepidemiol. 49 (2017) 142–151.
[7] K Bykov, K Yoshida, MG Weisskopf, JJ Gagne, Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis, Pharmacoepidemiol. Drug Saf. 26 (2017) 294–300.
[8] K-D Lin, C-Y Yang, M-Y Lee, et al, Statin therapy prevents the onset of Parkinson disease in patients with diabetes, Ann. Neurol. 80 (2016) 532–540.
[9] B Brakedal, K Haugarvoll, C Tzoulis, Simvastatin is associated with decreased risk of Parkinson disease, Ann. Neurol. 81 (2017) 329–330.
[10] Y-H Chang, S-J Yen, Y-H Chang, et al, Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus, Eur. J. Neurol. 28 (2021) 430–437.
[11] X Huang, A Alonso, X Guo, et al. Statins, plasma cholesterol, and risk of Parkinson’s disease: a prospective study, Mov. Disord. 30 (2015) 552–559.
[12] DK Arnett, RS Blumenthal, MA Albert, et al, 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation. 140 (2019) e596–e646.
[13] H Chohan, K Senkevich, RK Patel, et al, Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression, Mov. Disord. 36 (2021) 1420–1429.
[14] W Liu, J Tang, Association between diabetes mellitus and risk of Parkinson’s disease: A prisma-compliant meta-analysis, Brain. Behav. 11 (2021) e02082.
[15] AJ Hughes, SE Daniel, L Kilford, AJ Lees, Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases, J. Neurol. Neurosurg. Psychiatr. 55 (1992) 181–184.
[16] E Hentilä, M Tiihonen, H Taipale, et al, Incidence of antidepressant use among community dwellers with and without Parkinson’s disease - a nationwide cohort study, BMC. Geriatr. 21 (2021) 202.
[17] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2021 [Internet]. [2021 december 14];[cited 2022 Sep 20 ] Available from: www.whocc.no
[18] K Sunnarborg, M Tiihonen, M Huovinen, et al, Association between different diabetes medication classes and risk of Parkinson’s disease in people with diabetes, Pharmacoepidemiol. Drug Saf. 31 (2022) 875–882.
[19] A Samii, BC Carleton, M Etminan M, Statin use and the risk of Parkinson disease: a nested case control study, J. Clin. Neurosci. 15 (2008) 1272–1273.
[20] JH Kim, IB Chang, YH Kim, et al., Association between statin use and Parkinson’s disease in Korean patients with hyperlipidemia, Parkinsonism Relat. Disord. 97 (2022); 15–24.
[21] G Liu, NW Sterling, L Kong, et al., Statins may facilitate Parkinson’s disease: Insight gained from a large, national claims database, Mov. Disord. 32 (2017) 913–917.
[22] A Arfè, G Corrao, The lag-time approach improved drug-outcome association estimates in presence of protopathic bias, J. Clin. Epidemiol. 78 (2016); 101–107.
[23] A Paakinaho, N Karttunen, M Koponen, et al., Incidence of muscle relaxant use in relation to diagnosis of Parkinson’s disease, Int. J. Clin. Pharm. 42 (2020) 336–340.
[24] K Wang K, Z Luo, C Li, et al., Blood Cholesterol Decreases as Parkinson’s Disease Develops and Progresses, J. Parkinsons. Dis. 11 (2021) 1177–1186.
[25] J Joutsa, M Gardberg, M Röyttä, V Kaasinen, Diagnostic accuracy of parkinsonism syndromes by general neurologists, Parkinsonism Relat. Disord. 20 (2014) 840–844.
[26] G Rizzo, M Copetti, S Arcuti, et al. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis, Neurology. 86 (2016) 566–576.
[27] EF Schisterman, SR Cole, RW Platt, Overadjustment bias and unnecessary adjustment in epidemiologic studies, Epidemiology. 20 (2009) 488–495.
[28] L Cibičková, Statins and their influence on brain cholesterol. J. Clin. Lipidol. 5 (2011) 373–379.
[29] T Müller T, W Kuhn, D Pöhlau, H Przuntek, Parkinsonism unmasked by lovastatin, Ann. Neurol. 37 (1995) 685–686.